Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,FPHAF,-2414000.0,50457900,4172500,,-4796500,,-4801500,1271500,0,-4754500,-4754500,-689500,-11000,,,,5000,0,4754500,0,-42000,,-4801500,-4801500,565000.0,10216000.0,-1849000.0,258000.0,8367000.0,2691000.0,-96557000.0,786000.0,92017000.0,56000.0,4108000.0,6503000.0,122000.0,92017000.0,375000.0,7371000.0,1270000.0,2728000.0,2115000.0,939000,-31500,263000,977500,-857000,53000,-3759500,-121000,-4584500,76500,661500,58500,-1500,868000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,FARON PHARMACEUTICALS OY,False,False,PNK,4.7,1630503864,0.0,4.7,4.7,4.7,5000,POST,0,4,0.0,4.7 - 4.7,4.7,finmb_36632718,Faron Pharmaceuticals Oy,Other OTC,EUR,307,0,1.1499999,0.32394361,3.55 - 6.4431,-1.7431002,-0.2705375,3.55,6.4431,5.587222,-0.8872223,-0.15879488,5.0749874,-0.3749876,-0.07388937,237152128,15,America/New_York,EDT,-14400000,-0.27,,,6.4431,3.55,5.5872,5.075,307,,50.46M,,27.43M,42.70%,9.26%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-784.83%,-112.07%,,2.12M,0.05,,,-16.55M,-16.95M,,,4.11M,0.09,3.23M,,1.13,,-17.48M,-10.66M,Value,20520,Healthcare,30,"Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",Turku,358 2469 5151,1577750400,Finland,http://www.faron.com,86400,Joukahaisenkatu 6,358 2469 5152,Biotechnology,Intelligate
t-1,FPHAF,-2414000.0,50457900,4172500,,-4796500,,-4801500,1271500,0,-4754500,-4754500,-689500,-11000,,,,5000,0,4754500,0,-42000,,-4801500,-4801500,565000.0,10216000.0,-1849000.0,258000.0,8367000.0,2691000.0,-96557000.0,786000.0,92017000.0,56000.0,4108000.0,6503000.0,122000.0,92017000.0,375000.0,7371000.0,1270000.0,2728000.0,2115000.0,939000,-31500,263000,977500,-857000,53000,-3759500,-121000,-4584500,76500,661500,58500,-1500,868000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,FARON PHARMACEUTICALS OY,False,False,PNK,4.7,1630503864,0.0,4.7,4.7,4.7,5000,POST,0,4,0.0,4.7 - 4.7,4.7,finmb_36632718,Faron Pharmaceuticals Oy,Other OTC,EUR,307,0,1.1499999,0.32394361,3.55 - 6.4431,-1.7431002,-0.2705375,3.55,6.4431,5.587222,-0.8872223,-0.15879488,5.0749874,-0.3749876,-0.07388937,237152128,15,America/New_York,EDT,-14400000,-0.27,,,6.4431,3.55,5.5872,5.075,307,,50.46M,,27.43M,42.70%,9.26%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-784.83%,-112.07%,,2.12M,0.05,,,-16.55M,-16.95M,,,4.11M,0.09,3.23M,,1.13,,-17.48M,-10.66M,Value,20520,Healthcare,30,"Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",Turku,358 2469 5151,1577750400,Finland,http://www.faron.com,86400,Joukahaisenkatu 6,358 2469 5152,Biotechnology,Intelligate
t-2,FPHAF,6753000.0,50457900,2767000,,-3671500,,-3671500,1177000,0,-3572500,-3572500,-371500,-115000,,,,0,0,3572500,0,-99000,,-3671500,-3671500,560000.0,7030000.0,7313000.0,1529000.0,14343000.0,2691000.0,-87339000.0,,91961000.0,80000.0,11627000.0,4439000.0,,91961000.0,469000.0,13234000.0,,2303000.0,2729000.0,-118500,-39500,-106500,6416000,-399500,6998500,2284000,62500,-4155000,65000,-476000,-30500,-1000,8795000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,FARON PHARMACEUTICALS OY,False,False,PNK,4.7,1630503864,0.0,4.7,4.7,4.7,5000,POST,0,4,0.0,4.7 - 4.7,4.7,finmb_36632718,Faron Pharmaceuticals Oy,Other OTC,EUR,307,0,1.1499999,0.32394361,3.55 - 6.4431,-1.7431002,-0.2705375,3.55,6.4431,5.587222,-0.8872223,-0.15879488,5.0749874,-0.3749876,-0.07388937,237152128,15,America/New_York,EDT,-14400000,-0.27,,,6.4431,3.55,5.5872,5.075,307,,50.46M,,27.43M,42.70%,9.26%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-784.83%,-112.07%,,2.12M,0.05,,,-16.55M,-16.95M,,,4.11M,0.09,3.23M,,1.13,,-17.48M,-10.66M,Value,20520,Healthcare,30,"Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",Turku,358 2469 5151,1577750400,Finland,http://www.faron.com,86400,Joukahaisenkatu 6,358 2469 5152,Biotechnology,Intelligate
t-3,FPHAF,6753000.0,50457900,2767000,,-3671500,,-3671500,1177000,0,-3572500,-3572500,-371500,-115000,,,,0,0,3572500,0,-99000,,-3671500,-3671500,560000.0,7030000.0,7313000.0,1529000.0,14343000.0,2691000.0,-87339000.0,,91961000.0,80000.0,11627000.0,4439000.0,,91961000.0,469000.0,13234000.0,,2303000.0,2729000.0,-118500,-39500,-106500,6416000,-399500,6998500,2284000,62500,-4155000,65000,-476000,-30500,-1000,8795000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,FARON PHARMACEUTICALS OY,False,False,PNK,4.7,1630503864,0.0,4.7,4.7,4.7,5000,POST,0,4,0.0,4.7 - 4.7,4.7,finmb_36632718,Faron Pharmaceuticals Oy,Other OTC,EUR,307,0,1.1499999,0.32394361,3.55 - 6.4431,-1.7431002,-0.2705375,3.55,6.4431,5.587222,-0.8872223,-0.15879488,5.0749874,-0.3749876,-0.07388937,237152128,15,America/New_York,EDT,-14400000,-0.27,,,6.4431,3.55,5.5872,5.075,307,,50.46M,,27.43M,42.70%,9.26%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-784.83%,-112.07%,,2.12M,0.05,,,-16.55M,-16.95M,,,4.11M,0.09,3.23M,,1.13,,-17.48M,-10.66M,Value,20520,Healthcare,30,"Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",Turku,358 2469 5151,1577750400,Finland,http://www.faron.com,86400,Joukahaisenkatu 6,358 2469 5152,Biotechnology,Intelligate
